Month: March 2018

March 30, 2018
Long term outcomes in Finland

In Finland, all children with severe haemophilia are treated according to a single protocol, whether it’s delivered as part of comprehensive care or in a treatment centre. Outcomes can therefore be meaningfully compared for the entire haemophilia population – even if, in the case of a small country like Finland, that’s not many people. Specialists …

Read article
Factor storage affects patients satisfaction

Clinicians should remind patients that clotting factors don’t generally need to be stored in the fridge because, a study from Italy suggests, this may influence their satisfaction with treatment (Pat Pref Adherence 2018;12:431-41). The survey of 200 people with moderate or severe haemophilia A in seven countries (including the UK) determined how product features affected …

Read article
Novel biotechnology gains special EU status

A technology that could offer people with haemophilia B an implant providing long term Factor IX synthesis has been awarded Advanced Therapy Medicinal Product (ATMP) status by the European Medicines Agency’s Committee for Advanced Therapies. ATMPs are medicines for human use that are based on genes, tissues or cells that ‘offer ground breaking new opportunities …

Read article
New evidence of the impact of haemophilia on individuals and carers

Two new reports have confirmed how common pain and psychiatric morbidity are among people with haemophilia. B-HERO-S is a US study of 299 adults with haemophilia B and 150 carers which collected data by online survey (Eur J Haematol 2018; Mar 5. doi: 10.1111/ejh.13055). The prevalence of mild, moderate and severe haemophilia was 25%, 60% …

Read article